An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation

Article metrics

Abstract

B cell lymphoma and melanoma harbor recurrent mutations in the gene encoding the EZH2 histone methyltransferase (EZH2), but the carcinogenic role of these mutations is unclear. Here we describe a mouse model in which the most common somatic Ezh2 gain-of-function mutation (EZH2Y646F in human; Ezh2Y641F in mouse) is conditionally expressed. Expression of Ezh2Y641F in mouse B cells or melanocytes caused high-penetrance lymphoma or melanoma, respectively. Overexpression of the anti-apoptotic protein Bcl2, but not the oncoprotein Myc, or loss of the tumor suppressor protein p53 (encoded by Trp53 in mice) further accelerated lymphoma progression. Expression of the mutant Braf but not the mutant Nras oncoprotein further accelerated melanoma progression. Although expression of Ezh2Y641F globally increased the abundance of trimethylated Lys27 of histone H3 (H3K27me3), it also caused a widespread redistribution of this repressive mark, including a loss of H3K27me3 that was associated with increased transcription at many loci. These results suggest that Ezh2Y641F induces lymphoma and melanoma through a vast reorganization of chromatin structure, inducing both repression and activation of polycomb-regulated loci.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Design, oncogenic activity and genetic interactions of the Ezh2Y641F allele in B cells.
Figure 2: Mutated Ezh2Y641F genetically interacts with mutant BrafV600E but not NrasQ61R to induce melanoma.
Figure 3: Ezh2 inhibitors demonstrate anti-neoplastic activity in Ezh2Y641F-mutant cancers.
Figure 4: Gene expression in Ezh2Y641F reflects enrichment for PRC2 targets, H3K27me3-suppressed genes and a Myc signature.
Figure 5: Ezh2Y641F changes the genomic distribution and dynamics of H3K27me3.

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. 1

    Bernstein, B.E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006).

  2. 2

    Boyer, L.A. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349–353 (2006).

  3. 3

    Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H. & Helin, K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123–1136 (2006).

  4. 4

    Bracken, A.P. et al. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525–530 (2007).

  5. 5

    Kotake, Y. et al. pRB family proteins are required for H3K27 trimethylation and polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes Dev. 21, 49–54 (2007).

  6. 6

    Chen, H. et al. Polycomb protein Ezh2 regulates pancreatic beta cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975–985 (2009).

  7. 7

    Raaphorst, F.M. et al. Coexpression of BMI1 and EZH2 polycomb group genes in Reed–Sternberg cells of Hodgkin's disease. Am. J. Pathol. 157, 709–715 (2000).

  8. 8

    Visser, H.P. et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle-cell lymphoma. Br. J. Haematol. 112, 950–958 (2001).

  9. 9

    Su, I.H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124–131 (2003).

  10. 10

    Lessard, J. et al. Functional antagonism of the polycomb group genes Eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13, 2691–2703 (1999).

  11. 11

    van der Lugt, N.M. et al. Posterior transformation, neurological abnormalities and severe hematopoietic defects in mice with a targeted deletion of the Bmi1 proto-oncogene. Genes Dev. 8, 757–769 (1994).

  12. 12

    Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879–3884 (2012).

  13. 13

    Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).

  14. 14

    Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B cell lymphoma. Nature 471, 189–195 (2011).

  15. 15

    Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

  16. 16

    Forbes, S. et al. Cosmic 2005. Br. J. Cancer 94, 318–322 (2006).

  17. 17

    Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).

  18. 18

    Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667 (2010).

  19. 19

    Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298–301 (2012).

  20. 20

    Rickert, R.C., Roes, J. & Rajewsky, K. B lymphocyte–specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317–1318 (1997).

  21. 21

    Sneeringer, C.J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 107, 20980–20985 (2010).

  22. 22

    Béguelin, W. et al. EZH2 is required for germinal center formation, and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013).

  23. 23

    Morin, R.D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin's lymphoma. Nature 476, 298–303 (2011).

  24. 24

    Yap, D.B. et al. Somatic mutations at EZH2Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity to increase H3K27 trimethylation. Blood 117, 2451–2459 (2011).

  25. 25

    Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251–263 (2012).

  26. 26

    Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

  27. 27

    Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006–1014 (2012).

  28. 28

    Dankort, D. et al. A new mouse model to explore the initiation, progression and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379–384 (2007).

  29. 29

    Burd, C.E. et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 4, 1418–1429 (2014).

  30. 30

    Bosenberg, M. et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44, 262–267 (2006).

  31. 31

    Monahan, K.B. et al. Somatic p16INK4a loss accelerates melanomagenesis. Oncogene 29, 5809–5817 (2010).

  32. 32

    Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544–552 (2009).

  33. 33

    Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D. & Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).

  34. 34

    Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).

  35. 35

    Zuo, T. et al. Epigenetic silencing mediated through activated PI3K–AKT signaling in breast cancer. Cancer Res. 71, 1752–1762 (2011).

  36. 36

    Konze, K.D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324–1334 (2013).

  37. 37

    McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).

  38. 38

    Kamminga, L.M. et al. The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170–2179 (2006).

  39. 39

    Kondo, Y. et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741–750 (2008).

  40. 40

    Boylan, K.L. et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic and gene expression heterogeneity similar to human multiple myeloma. Cancer Res. 67, 4069–4078 (2007).

  41. 41

    Pasqualucci, L. et al. AID is required for germinal-center-derived lymphomagenesis. Nat. Genet. 40, 108–112 (2008).

  42. 42

    Mori, S. et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Eμ-Myc model and human diffuse large B cell lymphoma. Cancer Res. 68, 8525–8534 (2008).

  43. 43

    Pajic, A. et al. Cell cycle activation by c-Myc in a Burkitt lymphoma model cell line. Int. J. Cancer 87, 787–793 (2000).

  44. 44

    Sander, S. et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112, 4202–4212 (2008).

  45. 45

    Zhang, X. et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B cell lymphomas. Cancer Cell 22, 506–523 (2012).

  46. 46

    Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).

  47. 47

    Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008).

  48. 48

    Young, M.D. et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 39, 7415–7427 (2011).

  49. 49

    Jiao, L. & Liu, X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350, aac4383 (2015).

  50. 50

    McCabe, M.T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 109, 2989–2994 (2012).

  51. 51

    LaFave, L.M. et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21, 1344–1349 (2015).

  52. 52

    Bitler, B.G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231–238 (2015).

  53. 53

    Knutson, S.K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922–7927 (2013).

  54. 54

    Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).

  55. 55

    Goecks, J., Nekrutenko, A., Taylor, J. & Galaxy Team. Galaxy: a comprehensive approach for supporting accessible, reproducible and transparent computational research in the life sciences. Genome Biol. 11, R86 (2010).

  56. 56

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

Download references

Acknowledgements

We thank the UNC Lineberger Animal Histopathology Core, Flow Cytometry Core, Animal Models Core and Microscopy Services Laboratory for technical assistance, and the Mouse Phase 1 Unit (D. Darr and J. Roques) for providing animals and expertise. This work was supported by the US National Cancer Institute grants R01-CA163896 (N.E.S.), CA185353 (N.E.S.) and T32-CA009156 (G.P.S.), the US National Institute of Aging grant R01-AG024379 (N.E.S.) and the US National Heart, Lung and Blood Institute grant F32-HL117581 (G.P.S.).

Author information

G.P.S. and N.E.S. conceived the study, designed experiments and wrote the manuscript; G.P.S., J.-Y.L., J.X., J.P. and K.S.C. performed experiments; G.P.S., W.R.J., J.S.P. and J.M.S. analyzed sequencing data; Y.F. performed animal histopathology; C.E.B. generated the Nras animal models; J.E.B. and J.Q. designed and synthesized JQEZ5; and G.P.S., N.E.S., J.E.B., J.Q. and C.E.B. interpreted data.

Correspondence to Norman E Sharpless.

Ethics declarations

Competing interests

J.Q. and J.E.B. are inventors on a filed patent titled ‘Ezh2 inhibitors and uses thereof’. J.E.B. is now an employee, shareholder and executive at Novartis Pharmaceuticals.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–12 and Supplementary Tables 1–3 (PDF 18253 kb)

Source data

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Souroullas, G., Jeck, W., Parker, J. et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med 22, 632–640 (2016) doi:10.1038/nm.4092

Download citation

Further reading